Drug Injury Watch

Possible Andexxa Recall After FDA Does Not Approve the Anticoagulant Reversal Drug in December 2024

AstraZeneca Says "while discussions with the FDA are ongoing, Andexxa will remain on the US market."

 

(Posted by Tom Lamb at Drug Injury Watch)

 

In our November 21, 2024 article, "Do Andexxa Risks Outweigh Benefits Given Increased Rate of Thrombosis and Thrombosis-Related Deaths?", we previewed that discussions about this drug safety issue by an FDA Advisory Committee might lead to the withdrawal of Andexxa from the US market or, put otherwise, a possible Andexxa recall.

Now that this November 2024 Andexxa FDA Advisory Committee meeting has come and gone, we get an update on the current situation from a December 17, 2024, news report from FirstWord PHARMA, "Fate of AstraZeneca’s Andexxa unclear as FDA rejects full approval":

Less than a month after a bruising FDA advisory committee meeting, the agency has issued a complete response letter (CRL) regarding AstraZeneca's bid to convert its anticoagulant reversal drug Andexxa (andexanet alfa) from accelerated to full approval.

The fate of Andexxa is unclear at this stage; the FDA could seek withdrawal of the drug or ask for additional confirmatory data. AstraZeneca told FirstWord that "while discussions with the FDA are ongoing, Andexxa will remain on the US market."

Granted accelerated approval back in 2018 as an antidote for the reversal of Factor Xa inhibitors...

However, at last month's advisory meeting while discussing data from the ANNEXA-I confirmatory trial, panel members grappled with whether Andexxa's demonstrated benefits outweigh its risks. Ahead of the meeting, FDA reviewers highlighted "major safety findings," including a 14.6% thrombosis rate in the Andexxa arm of the study compared with 6.9% in the control group, along with higher thrombosis-related deaths.

__________________________________________________________________

Andexxa

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

For more details about this possible Andexxa recall, we go to a December 13, 2024, news report, "AstraZeneca Says Andexxa Will Not Convert To Full Approval, Quietly Reveals Complete Response", written by Sarah Karlin-Smith for Pink Sheet:

AstraZeneca PLC’s anticoagulant reversal agent Andexxa (andexanet) will not convert to full approval, the company told the Pink Sheet after the US Food and Drug Administration issued a complete response letter [(CRL)] for the supplemental biologics license application.

The next steps for the drug following the CRL, which has not been publicly announced by the company, are unclear. Neither AstraZeneca nor FDA would provide much additional information about the product’s standing....

The agency could move to withdraw the drug from the market or ask the company to conduct additional studies to verify a favorable risk-benefit balance.

AstraZeneca told the Pink Sheet that the drug will remain on the US market while discussions with the agency about next steps continue. But the company would not comment on whether those discussions include potential new trials.

Andexxa is the only treatment currently indicated to reduce the effects of direct oral FXa inhibitors, Bristol-Myers Squibb Co./Pfizer Inc.’s Eliquis (apixaban) and Johnson & Johnson/Bayer AG’s Xarelto (rivaroxaban), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

In summary, it seems the most one can say about this possible Andexxa recall is that it is unclear whether the FDA will seek withdrawal of this AstraZeneca anticoagulant reversal drug or request additional confirmatory data for Andexxa.

We will continue to watch for more developments concerning Andexxa, including whether its benefits outweigh its risks and this possible Andexxa recall.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation - Free. Confidential. No Obligation.

Novo Nordisk Semaglutide Drug Ozempic Linked to Vision Loss, Doubling the Risk: December 2024 Update

European Drug Regulators Are Investigating Semaglutide-Related NAION Cases Presented in Two Danish Studies

 

(Posted by Tom Lamb at Drug Injury Watch)

 

According to this December 18, 2024, Reuters news report, "Novo Nordisk's Ozempic faces EU review for potential eye disease connection", there is a significant development concerning semaglutide drugs like Ozempic linked to vision loss and blindness:

The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes drug Ozempic to a rare eye disease.

The studies published earlier this week had found Ozempic significantly increases the risk of type 2 diabetes patients developing NAION (non-arteritic anterior ischemic optic neuropathy), more than doubling the likelihood.  [emphasis added]

The European Medicines Agency (EMA) said late on [December 17, 2024] that the reviewed evidence from other research so far had not been strong enough to suggest a possible link between Ozempic and the eye disease but that the two Danish studies may hold new important information.

To provide context for this new European regulatory action on the drug safety issue of Ozempic linked to vision loss, we direct you to this December 16, 2024, Bloomberg article, "Ozempic Blinding Link in Study Prompts Agency to Seek Probe":

The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between Novo Nordisk A/S’s blockbuster shot Ozempic and a rare form of vision loss.

The national regulator will call on the European Committee for the Evaluation of Adverse Reactions, or PRAC, to assess the Danish registry studies, the agency said [December 16, 2024].

A pair of large studies from the University of Southern Denmark “strengthen the suspicion” of a link between Ozempic and the rare eye condition, called NAION, the agency said.

Conducted independently, the studies both found that people who took Ozempic faced more than twice the risk of the eye condition, which can cause blindness. Both appear to confirm a link first suggested earlier this year in a Harvard University study....

One of the two studies to prompt the call for a review appeared last week on medRxiv, a website that posts studies before they’re reviewed by outside scientists....

The second study examined data from about 424,000 Danish diabetes patients, of whom a quarter received Ozempic, and has been accepted for publication in the International Journal of Retina and Vitreous.

__________________________________________________________________

Ozempic / Wegovy / Rybelsus

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

The first study mentioned above, "Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study", was posted online on December 11, 2024. From the Abstract for that Danish study:

• Importance  Recent findings have raised concerns about an association between semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), and non-arteritic anterior ischemic optic neuropathy (NAION).
• Objective  To further investigate the putative association between semaglutide use and NAION.
• Participants  New users of semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) during 2018-2022 (Norway) and 2018-2024 (Denmark).
• Results  We identified 44,517 eligible users of semaglutide for the management of type 2 diabetes in Denmark and 16,860 in Norway. In total, we observed 32 NAION events among semaglutide users (24 in Denmark and 8 in Norway). This yielded an unadjusted incidence rate of NAION of 2.19/10,000 person-years among Danish semaglutide initiators, compared to 1.18 among SGLT-2i initiators. The corresponding unadjusted incidence rates in Norway were 2.90 and 0.92. After adjustment, we obtained a pooled [hazard ratios (HR)] of 2.81 (95% CI 1.67 to 4.75)...
• Conclusions and Relevance  Our findings show an association between use of semaglutide for type 2 diabetes and risk of NAION. However, the absolute risk remains low.

In closing, from our earlier reporting on this drug safety issue of Ozempic linked to vision loss, "Wegovy, Rybelsus, and Ozempic Eye Side Effects: Semaglutide Linked to NAION":

We are interested in hearing from patients who developed [nonarteritic anterior ischemic optic neuropathy (NAION)] following the use of Ozempic, Wegovy, or Rybelsus. We point out that NAION is sometimes referred to more simply as an “eye stroke" and, as it is a form of "optic neuropathy" (an eye disease category), NAION may be noted only as optic neuropathy in the medical records.

Patients who have been diagnosed with semaglutide-related NAION and experienced blindness or vision loss may be entitled to legal compensation by filing a drug injury lawsuit against Novo Nordisk, the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus.

We will continue to monitor the drug regulatory realm for more developments concerning semaglutide drugs like Ozempic linked to vision loss and blindness.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation - Free. Confidential. No Obligation.

Updated Ocaliva Liver Injury Warnings Are Issued By The FDA In December 2024

New Cases of Liver Transplants And Liver-Related Deaths Among Patients Who Did Not Have Cirrhosis

 

(Posted by Tom Lamb at Drug Injury Watch)

 

In a December 12, 2024, Drug Safety Communication the FDA said it had recently found cases of Ocaliva liver injury among patients who did not yet have cirrhosis, or scarring of the liver, including reports of liver transplants and liver-related deaths.

From that December 2024 FDA document, "Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis", we get this contextual information:

We previously identified that [primary biliary cholangitis (PBC)] patients with advanced cirrhosis were at risk of serious liver injury when taking Ocaliva and updated the prescribing information to restrict its use in these patients. FDA’s review of this required clinical trial found that some cases of liver injury in patients without cirrhosis resulted in liver transplant...

FDA restricted the use of Ocaliva in patients who have PBC with advanced cirrhosis of the liver in 2021 because it can cause serious harm in those patients, adding a new Contraindication to the Ocaliva prescribing information and patient Medication Guide. However, our recent review of case reports submitted to FDA* found that some patients with PBC and advanced cirrhosis were still taking the medicine despite these restrictions.

For additional background, we refer you to our previous Drug Injury Watch article about Ocaliva liver injury, "FDA Safety Evaluation Finds Ocaliva-related Liver Injury in Primary Biliary Cholangitis (PBC) Patients with Advanced Cirrhosis", written in May 2021.

__________________________________________________________________

Ocaliva

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

Returning to the December 2024 FDA Drug Safety Communication about Ocaliva liver injury, we get these details about the recently found cases:

FDA evaluated liver safety in the postmarket clinical trial in patients who were appropriate for Ocaliva treatment based on the approved indication in the prescribing information. Among these patients, the risk of both liver transplant and death were higher in patients receiving Ocaliva compared with those receiving placebo. Specifically, among patients for whom Ocaliva was indicated, which were those with a lower risk of progression to liver transplant or death, 7 of 81 who received Ocaliva needed a liver transplant compared to 1 of 68 patients who received placebo. An additional four patients receiving Ocaliva died, compared to one receiving placebo. Analyses evaluating the risk of liver transplant and death resulted in a hazard ratio of 4.77 (95% confidence interval: 1.03, 22.09) for patients without advanced cirrhosis and not contraindicated from receiving the drug. [Footnote omitted.]

As before, we will continue to monitor the drug regulatory realm for more developments on Ocaliva liver injury.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation - Free. Confidential. No Obligation.

Do Andexxa Risks Outweigh Benefits Given Increased Rate of Thrombosis and Thrombosis-Related Deaths?

Issue to be Considered by FDA Advisory Committee on November 21, 2024, and Discussion May Lead to Andexxa Drug Recall

 

(Posted by Tom Lamb at Drug Injury Watch)

 

At its November 21, 2024 meeting, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will discuss whether Andexxa risks outweigh benefits. From the October 2024 FDA Briefing Document for that Andexxa Advisory Committee meeting comes this Draft Discussion Question:

ANNEXA-I demonstrated an increased incidence of thrombosis (15.1% versus 6.9%) and thrombosis-related deaths at Day 30 (2.5% versus 0.9%) in the [Andexxa (andexanet)] arm compared to the [usual care (UC)]. Are the serious risks of [Andexxa (andexanet)] acceptable in the indicated population and in the context of the benefit demonstrated in ANNEXA-I?

For some contextual information, we turn to this November 19, 2024 Endpoints News report "Ahead of adcomm, FDA raises safety questions for AstraZeneca’s reversal agent for life-threatening bleeds", by Zachary Brennan, Senior Editor:

[Andexxa (andexanet)], a recombinant modified human factor Xa protein, is for patients treated with [Xarelto (rivaroxaban)] or [Eliquis (apixaban)] when rapid reversal of anticoagulation is needed because of life-threatening or uncontrolled bleeding. That could include, for example, when a patient needed urgent surgery because of a medical emergency or accident.

Last year, AstraZeneca began plans to shift Andexxa to a full approval from its accelerated approval after halting its confirmatory trial early due to these efficacy findings.

But FDA explained how the confirmatory trial, known as ANNEXA-I, revealed “major safety findings” including a “doubling of the rate of thromboses and thrombosis related deaths at Day 30 in the [Andexxa (andexanet)] arm compared with” a standard of care clotting agent known as a prothrombin complex concentrate.

Of the 239 patients treated with [Andexxa (andexanet)], FDA said, 14.6% of patients suffered thrombotic events versus 6.9% in the standard of care arm.

Essentially, as regards the issue of whether Andexxa risks outweigh benefits, the FDA wants this Andexxa Advisory Committee to look into the increased rates of dangerous clotting and clotting-related deaths seen in the ANNEXA-I trial done for Andexxa, compared with a standard of care reversal agent.

__________________________________________________________________

Andexxa

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

For more specificity, we return to the October 2024 FDA Briefing Document and go to the Topics for Discussion part:

4.1. Increased Risk of Thrombosis of Treatment with [Andexxa (andexanet)]

The rate of thrombotic events among patients treated with [Andexxa (andexanet)] is double the rate of those who were treated with [usual care (UC)]. Of patients treated with andexanet, 14.6% suffered [thrombotic events (TEs)] versus 6.9% in the [usual care (UC)] arm.

Thrombotic events in the [Andexxa (andexanet)] arm tended to occur earlier at median day 3.5, compared with median day 16 in the UC arm. Such early [thrombotic event (TE)] onset may preclude attempts at prophylactic anticoagulant resumption.

Of those patients who resumed prophylactic anticoagulation, 9.6% in the [Andexxa (andexanet)] arm and 5.5% in the UC arm developed TEs. More than half of the 35 patients experiencing a TE after [Andexxa (andexanet)] treatment had their first TE within 3 days of randomization, a period when anticoagulation is generally not feasible due to bleeding concerns, and therefore did not receive prophylactic anticoagulation....

Death rates were comparable between the treatment arms with 28.0% in the [Andexxa (andexanet)] group and 26.3% in the UC arm, however, deaths attributable to TEs were more twice as high in the [Andexxa (andexanet)] arm than in the UC arm.

Even before this Andexxa Advisory Committee meeting was convened, there was speculation that it might lead to an eventual Andexxa drug recall. For example, here is an article published November 20, 2024, by Pink Sheet, "AstraZeneca’s Andexxa Could Be Headed For Withdrawal After US FDA’s Negative Advisory Committee Preview":

AstraZeneca PLC’s Andexxa may face withdrawal after the US Food and Drug Administration raised concerns about its clinical efficacy, as well as serious safety events seen in the anticoagulant reversal agent’s confirmatory study in briefing documents ahead of a 21 November advisory committee.

We will continue to monitor this emerging drug safety issue of whether Andexxa risks outweigh benefits.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation - Free. Confidential. No Obligation.

Side Effects of Birth Control: Brain Tumors Related to Depo-Provera Contraceptive Injections

Intracranial Meningioma Risks Are Increased When Depo-Provera Was Used for More Than One Year

 

(Posted by Tom Lamb at Drug Injury Watch)

 

A medical journal article published in March 2024 reported that Depo-Provera (medroxyprogesterone acetate) increased the risk of intracranial meningioma by 5.6 times if Depo-Provera was used as birth control for longer than a year.

The contraceptive injection Depo-Provera being linked to brain tumors in some women is a still emerging drug safety issue that has recently resulted in some drug injury lawsuits seeking legal compensation being filed against the responsible pharmaceutical companies.

Intracranial meningiomas are mostly non-cancerous or non-malignant tumors that grow in layers of tissue covering the brain and spinal cord. However, cancerous or malignant meningiomas account for 40% of cancers in the central nervous system.  Both of these forms of intracranial meningioma are potentially serious medical conditions.

__________________________________________________________________

Depo-Provera Contraceptive Injection

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

This March 2024 BMJ article, "Use of progestogens and the risk of intracranial meningioma: national case-control study", provides these details about the increased risk of intracranial meningioma associated with the use of Depo-Provera, a widely used injectable birth control or contraceptive product in the US and around the world.

• "Meningiomas account for 40% of primary tumours of the central nervous system. The incidence of meningioma in the United States is 9.5 per 100 000 person years. Meningiomas are mostly slow growing, histologically benign tumours but can nevertheless compress adjacent brain tissue and thus patients may require surgical decompression. The incidence of meningiomas increases with age, rising sharply after the age of 65 years. Conversely, meningiomas are rare before the age of 35." [Footnotes omitted.]
• An excess risk of meningioma (odds ratio 5.55 (2.27 to 13.56)) was associated with the use of Depo-Provera (medroxyprogesterone acetate).
• Meningiomas before age 45 years were rare (n=3/9) in cases of exposure to Depo-Provera (medroxyprogesterone acetate).

If you are interested in reviewing some general medical information about meningioma, we direct you to the Mayo Clinic's "Symptoms & causes" and "Diagnosis & treatment" web pages.

We point out that the current drug label information for Depo-Provera Contraceptive Injection (Depo-Provera CI), version "Revised: 7/2024", does not include any warning about an increased risk of intracranial meningioma.

For this reason, i.e., failure to warn, we are investigating cases of the contraceptive injection Depo-Provera being linked to brain tumors in some women as possible drug injury lawsuits against the responsible pharmaceutical companies.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation - Free. Confidential. No Obligation.

Veozah Liver Injury Drug Safety Communication Issued by FDA in September 2024

August 2024 Veozah Drug Label Change Adds Warnings About Liver Toxicity and Abnormal Liver Tests

 

(Posted by Tom Lamb at Drug Injury Watch)

---

UPDATE: From 12/17/24 FDA Division of Drug Information email "Updated Drug Safety Communication on Veozah (fezolinetant)": 

FDA added a Boxed Warning, our most prominent warning, to highlight the known risk of rare but serious liver injury associated with use of menopause medicine Veozah (fezolinetant).

In September, the FDA issued a drug safety communication warning that Veozah can cause rare but serious liver injury. If there are signs and symptoms suggesting liver injury, stopping the medicine could prevent worsening liver injury and potentially return liver function to normal.

Read the full Drug Safety Communication.

Refer to the updated product labeling for more information.

(12/17/24)

---

On September 12, 2024, the FDA announced a warning about the rare occurrence of serious liver injury when a woman is using Veozah for hot flashes due to menopause. This Veozah liver injury FDA Drug Safety Communication instructed patients and doctors to stop Veozah if signs and symptoms of liver injury occur.

In more detail, from the "Additional Information for Patients" section of that September 2024 FDA Veozah liver injury document:

Stop taking Veozah immediately and contact your health professional who prescribed the medicine if you experience signs and symptoms that suggest liver problems. These may include feeling more tired than usual; nausea; vomiting; unusual itching; light-colored stools; yellowing of the eyes or skin, called jaundice; dark urine; swelling in the stomach or belly area, called the abdomen; or pain in the right upper abdomen. Stopping the medicine if there are signs and symptoms that suggest liver injury could prevent worsening liver injury and potentially return liver function to normal.

As background, Veozah (fezolinetant) was approved by the FDA in May 2023 to reduce the frequency and severity of moderate to severe hot flashes caused by menopause, or more exactly "for the treatment of moderate to severe vasomotor symptoms due to menopause".

That more precise information and the newly added Veozah liver injury warnings are included in the Veozah Prescribing Information document, or drug label, "Revised: 8/2024" version. 

__________________________________________________________________

Veozah

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

In particular, through an FDA Supplemental Approval letter sent to Astellas Pharma US, Inc., which is dated 8/31/2024, several new paragraphs were added to this important part of the Veozah drug label: 5 WARNINGS AND PRECAUTIONS, 5.1 Hepatic Transaminase Elevation and Hepatotoxicity.

There may be some women who were using Veozah and then diagnosed with a serious liver injury at some point between May 2023 to August 2024, the period when the additional information found in those new paragraphs was not in the Veozah drug label. For those women, there are possible drug injury lawsuits that would be filed against Astellas Pharma for failure to adequately warn about liver toxicity and abnormal liver tests associated with Veozah use.

We will continue to monitor developments regarding this new Veozah liver injury drug safety issue.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation - Free. Confidential. No Obligation.

Syfovre Injections Side Effects Legal Compensation Cases Being Filed for Patients

Drug Company Apellis Failed to Warn About Retinal Vasculitis Until a November 2023 Label Change

 

(Posted by Tom Lamb at Drug Injury Watch)

 

We are handling Syfovre injections side effects legal compensation cases being filed for patients The basis for these product liability personal injury lawsuits is the drug company Apellis failed to warn about retinal vasculitis until a November 2023 label change.

In more detail, Syfovre (pegcetacoplan) is an eye-injection drug for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) from Apellis Pharmaceuticals. The FDA approved it on February 17, 2023.

Syfovre injections side effects include occlusive retinal vasculitis, which is a type of eye inflammation that blocks blood flow to the retina, resulting in vision loss and potentially causing blindness. There have also been reported cases of non-occlusive retinal vasculitis and other types of eye inflammation.

The Journal of VitreoRetinal Diseases (JVRD), which is the peer-reviewed journal of the American Society of Retina Specialists (ASRS), published a general report on Syfovre retinal-related vision loss, co-authored by members of the ASRS Research and Safety in Therapeutics (ReST) Committee. This report revealed that at least 13 patients had Syfovre retinal-related vision loss in 2023.

That December 2023 JVRD ASRS ReST report article, "Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee", considered 14 eyes of 13 patients who developed retinal vasculitis after their first Syfovre injection. For this set of Syfovre retinal-related vision loss cases, the ASRS ReST report provided these findings:

• 11 eyes were diagnosed as having developed occlusive vasculitis after a Syfovre injection;
• 6 0f 14 eyes had significant vision loss, having lost more than 6 lines of vision; and,
• 2 eyes required enucleation, a surgical procedure that involves the removal of the entire eye.

A November 2023 label change added new Syfovre warnings for retinal vascular occlusion and retinal vasculitis cases associated with Syfovre injections. With these new Syfovre injections side effects warnings, it now seems that the retinal vascular occlusion and retinal vasculitis cases associated with Syfovre use are due to the drug itself and not the injection kits, as had been suggested earlier by Apellis Pharmaceuticals.

__________________________________________________________________

Syfovre

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

Returning to the American Society of Retina Specialists (ASRS), we get the latest from this July 19, 2024 news report, "The Syfovre Balancing Act. The Retinal Vasculitis Risk Is Real But Research Also Points to Benefits | ASRS 2024":

Last year’s annual meeting of the American Society of Retina Specialists (ASRS) was rocked by news that a small but notable number of patients treated with Syfovre (pegacetacoplan), the first-ever, FDA-approved treatment for geographic atrophy, developed retinal vasculitis, a serious complication that can lead to severe, permanent vision loss. The ASRS Research and Safety in Therapeutics Committee provided an almost day-by-day timeline and details on what was then a handful of cases.

At this year’s ASRS meeting in Stockholm, Sweden, this week, Syfovre’s risks and benefits were still a featured topic but the sense of urgency mellowed into the calmer territory more typical of medical conferences: discrepant findings and differing emphasis on risk and benefits but also points of agreement.

The combined results of two real-world evidence studies presented Thursday put the risk of developing retinal vasculitis at about 1 in every 1,330 patients....

We have been following Syfovre drug safety developments having to do with retinal vascular occlusion and retinal vasculitis cases as well as other eye-related Syfovre side effects since July 2023. These are the five most recent articles we have written about Syfovre injections side effects:

1. Syfovre Safety-Benefit Assessment by Europe's Drug Regulator Differs From FDA (6/28/2024)
2. Syfovre Retinal Vaso-occlusive Vasculitis Case Report Involving 78-year Old Woman With Vision Loss (4/24/2024)
3. Syfovre Case Report: Occlusive Retinal Vasculitis Shortly After Patient's First Syfovre Injection (3/6/2024)
4. Syfovre Safety Issues Need More Attention Before This Relatively New Eye Drug Gets Widely Prescribed (12/27/2023)
5. Syfovre Update: New Warnings About Retinal Vasculitis and/or Retinal Vascular Occlusion After Syfovre Injections (12/4/2023)

As stated at the beginning of this article, we are handling Syfovre injections side effects legal compensation cases being filed for patients as product liability personal injury lawsuits filed against the drug company Apellis. We have a free online Syfovre Case Evaluation for these Syfovre lawsuits, or you can call us toll-free at 800-426-9535.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation - Free. Confidential. No Obligation.

No Warnings About Blood Clots From Ozempic, Wegovy, and Rybelsus in Drug Labels

Growing Number of Pulmonary Embolism and DVT Cases Involving Semaglutide Reported by Patients

 

(Posted by Tom Lamb at Drug Injury Watch)

 

Wegovy, Rybelsus, and Ozempic have been associated with an increased risk of blood clots that can lead to pulmonary embolism (sometimes called PE) and deep vein thrombosis (often called DVT). However, there are no warnings about blood clots from Ozempic, Wegovy, and Rybelsus in their current Prescribing Information document, commonly called the drug label.

Wegovy, Rybelsus, and Ozempic are drugs with semaglutide as their active ingredient. As we first reported in this February 2024 article, "'New' Blood Clots Side Effect of Semaglutide Weight Loss Drugs Like Ozempic: Deep Vein Thrombosis", it is the semaglutide that has been linked to blood clots:

Somewhat hidden in a relatively recent medical journal article is the mention of a blood clots side effect of semaglutide weight-loss drugs like Ozempic, deep vein thrombosis (DVT). Remarkably, medical researchers found that semaglutide increased the risk of deep vein thrombosis by 266% when doing a study to assess the risk of semaglutide in leading to various serious adverse events (SAEs) in patients with type 2 diabetes.

DVT and Pulmonary Embolism Involving Semaglutide Drugs

Here are some representative case reports of DVT and pulmonary embolism involving semaglutide drugs:

Ozempic - Deep vein thrombosis (DVT) and pulmonary embolism were diagnosed in a 66-year-old woman who had been using Ozempic for 2 months.

Ozempic - Pulmonary embolism (PE) and DVT were diagnosed in a 53-year-old man who had been using Ozempic for 1 year.

Ozempic - Blood clots in both lungs, which is a bilateral pulmonary embolism, were diagnosed in a 46-year-old woman who had been using Ozempic for 2 months.

Rybelsus - DVT was diagnosed in a 62-year-old woman who had been using Rybelsus for 1 month.

 

Other Blood Clot-Related Conditions Involving Semaglutide Drugs

Here are some representative case reports of other blood clot conditions involving semaglutide drugs:

Ozempic - Blood clot in the portal vein, or portal vein thrombosis (PVT), was diagnosed in a 44-year-old woman who had been using Ozempic for 2 weeks.

Wegovy - Ischemic stroke was diagnosed in a 45-year-old man who had been using Wegovy for 3 months.

__________________________________________________________________

Ozempic / Wegovy / Rybelsus

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

No Blood Clot Warnings for Ozempic, Wegovy, and Rybelsus

The current Prescribing Information documents, or drug labels, for Ozempic, Wegovy, and Rybelsus (accessed 7/18/24) do not include any blood clot warnings. As seen below, in the warnings section of those drug labels there is nothing about deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), ischemic stroke, or any other blood clot-related side effects.

• Ozempic (Revised: 9/2023) [PDF]: 5 WARNINGS AND PRECAUTIONS  5.1 Risk of Thyroid C-Cel Tumors  5.2 Pancreatitis  5.3 Diabetic Retinopathy Complications  5.4 Never Share an OZEMPIC Pen Between Patients  5.5 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin  5.6 Acute Kidney Injury  5.7 Hypersensitivity  5.8 Acute Galbladder Disease
• Wegovy (Revised: 3/2024) [PDF]: 5 WARNINGS AND PRECAUTIONS  5.1 Risk of Thyroid C-Cel Tumors  5.2 Acute Pancreatitis  5.3 Acute Galbladder Disease  5.4 Hypoglycemia  5.5 Acute Kidney Injury  5.6 Hypersensitivity Reactions  5.7 Diabetic Retinopathy Complications in Patients with Type 2 Diabetes  5.8 Heart Rate Increase  5.9 Suicidal Behavior and Ideation
• Rybelsus (Revised: 1/2024) [PDF]: 5 WARNINGS AND PRECAUTIONS  5.1 Risk of Thyroid C-Cel Tumors  5.2 Pancreatitis  5.3 Diabetic Retinopathy Complications  5.4 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin  5.5 Acute Kidney Injury  5.6 Hypersensitivity  5.7 Acute Galbladder Disease

 

We have been investigating possible Ozempic, Rybelsus, and Wegovy drug injury lawsuits for people diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), ischemic stroke, or any other blood clot-related side effects.

Let us know if we can assist you or someone you know. One way to do this is to submit an online Case Evaluation Form.

Of course, we will continue to watch for developments concerning this relatively new drug safety issue of Wegovy, Rybelsus, and Ozempic being linked to blood clots.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation - Free. Confidential. No Obligation.

Wegovy, Rybelsus, and Ozempic Eye Side Effects: Semaglutide Linked to NAION

Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), or "Eye Stroke", Can Cause Vision Loss

 

(Posted by Tom Lamb at Drug Injury Watch)

 

Wegovy, Rybelsus, and Ozempic eye side effects are possible given the recent findings that the active ingredient of these three drugs semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION).

As background, NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma.

We begin our reporting on the new semaglutide side effects findings with this July 3, 2024, STAT news article, "Study links Ozempic to higher risk of eye condition that can cause vision loss":

A new observational study on [July 3, 2024] reported for the first time a potential link between Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss.

After hearing anecdotes of patients on the diabetes and obesity drugs experiencing nonarteritic anterior ischemic optic neuropathy, or NAION, researchers at Massachusetts Eye and Ear analyzed data from a registry of patients at their institution to see if there was a broad trend....

In both the diabetes and obesity cohorts that got semaglutide, the researchers found that NAION cases occurred most frequently in the first year after the medications were prescribed.

NAION, sometimes referred to as an “eye stroke,” occurs from a lack of sufficient blood flow to the optic nerve. It typically causes sudden vision loss and, in severe cases, can lead to blindness. There are currently no proven treatments for the condition.

__________________________________________________________________

Ozempic / Wegovy / Rybelsus

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

The medical journal article that presented the new semaglutide eye side effects findings, "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide", was published on July 3, 2024, by JAMA Ophthalmology, and begins with this Key Points section:

• Question  Are prescriptions for semaglutide associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes or patients who are overweight or obese?
• Findings  This matched cohort study of 16 827 patients revealed higher risk of NAION in patients prescribed semaglutide compared with patients prescribed non–glucagon-like peptide receptor agonist medications for diabetes or obesity.
• Meaning  The findings suggest a potential risk of NAION associated with prescriptions for semaglutide, but future study is required to assess causality.

A good summary of these Wegovy, Rybelsus, and Ozempic (semaglutide) eye side effects findings was provided in this July 3, 2024, MedPage Today article, "Semaglutide May Be Linked to Condition That Causes Blindness":

Over a mean follow-up of nearly 3 years, patients with diabetes on semaglutide had more than a fourfold higher risk for developing nonarteritic anterior ischemic optic neuropathy (NAION) compared with patients not on a GLP-1 agonist (HR 4.28, 95% CI 1.62-11.29, P<0.001), reported Joseph Rizzo III, MD, of Massachusetts Eye and Ear and Harvard Medical School in Boston, and colleagues.

Those prescribed semaglutide for overweight or obesity had an over sevenfold higher risk for NAION (HR 7.64, 95% CI 2.21-26.36, P<0.001), a significant cause of blindness, they wrote in JAMA Ophthalmology.

Over 3 years, the cumulative incidence of NAION were 8.9% and 6.7% in the two semaglutide groups, respectively, versus 1.8% and 0.8% for the non-GLP-1 groups.

"Despite evidence of neuroprotective properties, expression of the GLP-1 receptor in the human optic nerve and GLP-1 [receptor agonist] RA-induced enhanced sympathetic nervous system activity might influence optic nerve head perfusion and potentially increase the risk of NAION," suggested Rizzo and co-authors.

We are interested in hearing from patients who developed NAION following the use of Ozempic, Wegovy, or Rybelsus. We point out that NAION is sometimes referred to more simply as an “eye stroke" and, as it is a form of "optic neuropathy" (an eye disease category), NAION may be noted only as optic neuropathy in the medical records.

Patients who have been diagnosed with semaglutide-related NAION and experienced blindness or vision loss may be entitled to legal compensation by filing a drug injury lawsuit against Novo Nordisk, the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation - Free. Confidential. No Obligation.

Syfovre Safety-Benefit Assessment by Europe's Drug Regulator Differs From FDA

EMA’s CHMP Does Not Approve Syfovre for a Second Time, Citing "significant risk of adverse events"

 

(Posted by Tom Lamb at Drug Injury Watch)

 

There seems to be some disagreement about the Syfovre safety-benefit assessment when it comes to the US FDA and its European counterpart, the European Medicines Agency (EMA).

In late June 2024, Europe’s drug regulator, the Committee for Medicinal Products for Human Use (CHMP), did not approve Syfovre for a second time, with Apellis Pharmaceuticals asserting it will continue its efforts to market Syfovre in Europe.

From this Fierce Pharma June 28, 2024 article, "EU's drug regulator again rejects Apellis' eye med....", we get the latest on what is happening with Syfovre in Europe:

For the second time in six months, Europe’s Committee for Medicinal Products for Human Use (CHMP) has given a thumbs down to Apellis’ Syfovre for the treatment of patients with geographic atrophy (GA) caused by age-related macular degeneration.

In a release, Apellis noted that there were “multiple dissenting votes” by CHMP members to the opinion. The company added that it plans to seek a reexamination of the opinion, with a final decision expected in the fourth quarter of this year.

“Although the studies showed that Syfovre slowed the growth of geographic atrophy lesions, this did not lead to clinically meaningful benefits for patients,” the CHMP said. “It was noted that benefits of a treatment should impact patients’ everyday functioning, and this was not demonstrated in the studies.”

“In terms of safety,” the CHMP continued, “regular injections into the eye carry a significant risk of adverse events, including the development of other forms of AMD or inflammation in the eye, that could further worsen vision.”

In January of this year, the CHMP adopted its first negative opinion on Syfovre. The drug was approved by the FDA in February of 2023 and generated $275 million in sales last year despite early reports of inflammation for some users.

__________________________________________________________________

Syfovre

Free Case Evaluation

Strictly Confidential, No Obligation.

__________________________________________________________________

 

For more detail, we get this information from the updated Syfovre (pegcetacoplan) page on the EMA's website (accessed 6/28/24):

The European Medicines Agency has recommended the refusal of the marketing authorisation for Syfovre, a medicine intended for the treatment of geographic atrophy caused by age-related macular degeneration (AMD)....

The Agency issued its opinion on 27 June 2024....

What were the main reasons for refusing the marketing authorisation?

Although the studies showed that Syfovre slowed the growth of geographic atrophy lesions, this did not lead to clinically meaningful benefits for patients. It was noted that benefits of a treatment should impact patients’ everyday functioning, and this was not demonstrated in the studies. In terms of safety, regular injections into the eye carry a significant risk of adverse events, including the development of other forms of AMD or inflammation in the eye, that could further worsen vision. Therefore, the Agency’s opinion was that a positive balance of benefits and risks of Syfovre in the treatment of geographic atrophy caused by AMD could not be established and it recommended refusing marketing authorisation.

As we have reported previously, Syfovre side effects include occlusive retinal vasculitis, which is a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and potentially causing blindness. There have also been cases of non-occlusive retinal vasculitis and other types of eye inflammation.

We have been monitoring this Syfovre drug safety issue since July 2023 on Drug Injury Watch, and these are the four most recent articles:

• Syfovre Retinal Vaso-occlusive Vasculitis Case Report Involving 78-year Old Woman With Vision Loss (4/24/2024)
  
  
• Syfovre Case Report: Occlusive Retinal Vasculitis Shortly After Patient's First Syfovre Injection (3/6/2024)
  
  
• Syfovre Safety Issues Need More Attention Before This Relatively New Eye Drug Gets Widely Prescribed (12/27/2023)
  
  
• Syfovre Update: New Warnings About Retinal Vasculitis and/or Retinal Vascular Occlusion After Syfovre Injections (12/4/2023)
  
  

We continue to investigate possible Syfovre drug injury lawsuits for patients who developed retinal vasculitis or retinal vascular occlusion with resulting vision loss or blindness after their Syfovre injection. These Syfovre lawsuits would be filed against Apellis Pharmaceuticals, the drug company responsible for Syfovre -- not the patient's eye doctor.

DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects

Drug Injury Case Evaluation - Free. Confidential. No Obligation.